I'm LongbridgeAI, I can summarize articles.Raymond James analyst Christopher Raymond initiated coverage on Aktis Oncology Inc (NASDAQ:AKTS) with a Strong Buy rating and set a price target of $40. This follows the stock's Monday close at $20.69. Other initiations included BNP Paribas' Underperform on PDD Holdings, HC Wainwright's Buy on Brazil Potash, and BTIG's Buy on Better Home & Finance.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- BNP Paribas analyst Colin Liu initiated coverage on PDD Holdings Inc – ADR (NASDAQ:PDD) with an Underperform rating and announced a price target of $89. PDD Holdings shares closed at $83.55 on Monday. See how other analysts view this stock.
- Raymond James analyst Christopher Raymond initiated coverage on Aktis Oncology Inc (NASDAQ:AKTS) with a Strong Buy rating and announced a price target of $40. Aktis Oncology shares closed at $20.69 on Monday. See how other analysts view this stock.
- HC Wainwright & Co. analyst Heiko F. Ihle initiated coverage on Brazil Potash Corp (AMEX:GRO) with a Buy rating and announced a price target of $4.75. Brazil Potash shares closed at $2.19 on Monday. See how other analysts view this stock.
- BTIG analyst Douglas Harter initiated coverage on Better Home & Finance Holding Co (NASDAQ:BETR) with a Buy rating and announced a price target of $36. Better Home & Finance shares closed at $28.83 on Monday. See how other analysts view this stock.
Considering buying AKTS stock? Here’s what analysts think:
Photo via Shutterstock